Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FTSV

Forty Seven (FTSV) Stock Price, News & Analysis

Forty Seven logo

About Forty Seven Stock (NASDAQ:FTSV)

Advanced Chart

Key Stats

Today's Range
$95.51
$95.51
50-Day Range
$95.51
$95.51
52-Week Range
$5.53
$95.51
Volume
N/A
Average Volume
1.61 million shs
Market Capitalization
$4.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Receive FTSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Forty Seven and its competitors with MarketBeat's FREE daily newsletter.

FTSV Stock News Headlines

Janus Henderson Forty D
An AI run of epic proportions is only getting started
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
Janus Henderson Forty T
Janus Henderson Forty S
See More Headlines

FTSV Stock Analysis - Frequently Asked Questions

Forty Seven Inc (NASDAQ:FTSV) announced its earnings results on Tuesday, November, 12th. The company reported ($0.38) EPS for the quarter, meeting analysts' consensus estimates of ($0.38). The business had revenue of $15.68 million for the quarter, compared to the consensus estimate of $15.80 million.

Forty Seven (FTSV) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Forty Seven investors own include Gilead Sciences (GILD), TG Therapeutics (TGTX), Clovis Oncology (CLVS), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Abbott Laboratories (ABT) and ACADIA Pharmaceuticals (ACAD).

Company Calendar

Last Earnings
11/12/2019
Today
6/06/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FTSV
CIK
N/A
Fax
N/A
Employees
57
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$87.62 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$15.68 million
Price / Cash Flow
N/A
Book Value
$7.52 per share
Price / Book
12.70

Miscellaneous

Free Float
N/A
Market Cap
$4.60 billion
Optionable
Not Optionable
Beta
0.40
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:FTSV) was last updated on 6/6/2025 by MarketBeat.com Staff
From Our Partners